Viatris Must Face Novo Nordisk Ozempic Patent Claims in Delaware

Viatris Inc. failed to convince a judicial panel on multidistrict litigation that Novo Nordisk AS’s patent-infringement suit over a proposed copy of the blockbuster diabetes drug Ozempic should remain in West Virginia, according to an order transferring the case to Delaware.

Chair Karen K. Caldwell, in a transfer order issued Aug. 5 by the US Judicial Panel on Multidistrict Litigation, rejected an argument by Viatris’ Mylan Pharmaceuticals Inc. that “most of the patents asserted against it relate to the injection pen for delivering the medication, rather than the formulation and use of semaglutide,” Ozempic’s active ingredient.

The West Virginia ...